Abstract
In this perspective, we present our assessment of all of the known accumulated evidence on the role of neoadjuvant therapy in the management of borderline resectable pancreatic cancer highlighting the gaps in the data, the current regimens used and providing a brief insight into the way forward.
Original language | English |
---|---|
Number of pages | 6 |
Journal | Indian Journal of Surgical Oncology |
DOIs | |
Publication status | E-pub ahead of print - 1 Jul 2021 |
Keywords
- Neodajuvant Therapy
- Pancreatic Cancer